NCT05129774

Brief Summary

In left-sided colon and rectal cancer, the occurrence of synchronous para-aortic lymph node metastasis is rare, with the incidence of being approximate 1-2%. Currently, there has been no standard treatment strategy for this situation. The present trial is designed to evaluate the safety and efficacy of para-aortic lymph node dissection for left-sided colon and rectal cancer with synchronous para-aortic lymph node metastasis

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
8mo left

Started Jan 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress87%
Jan 2022Jan 2027

First Submitted

Initial submission to the registry

October 28, 2021

Completed
25 days until next milestone

First Posted

Study publicly available on registry

November 22, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2027

Expected
Last Updated

November 22, 2021

Status Verified

October 1, 2021

Enrollment Period

2 years

First QC Date

October 28, 2021

Last Update Submit

November 18, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • 5-year OS

    5-year overall survival

    From date of recruitment until the date of death from any cause, assessed up to 5 years

Secondary Outcomes (3)

  • DFS

    From date of recruitment until the date of disease recurrece, assessed up to 5 years

  • LFFS

    From date of recruitment until the date of para-aortic lymph node recurrence, assessed up to 3 years

  • Postoperative complications

    From date of surgery until the date of 30 days after surgery

Study Arms (2)

radical surgery with PALND

EXPERIMENTAL
Procedure: Radical surgery with PALND

radical surgery without PALND

ACTIVE COMPARATOR
Procedure: Radical surgery without PALND

Interventions

sufficient resection margins of the tumor, D3 dissection of the regional lymph nodes and para-aortic lymph node dissection from the bifurcation of iliac artery to the left renal vein via laparoscopic approach

radical surgery with PALND

surgery includes sufficient resection margins of the tumor and D3 dissection of the regional lymph nodes without PALND

radical surgery without PALND

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age at enrollment is ≥ 18 and ≤ 75 years
  • ECOG PS 0-1
  • histologically confirmed left-sided colon and rectal carcinoma
  • synchronous para-aortic lymph node metastases confirmed by PET-CT, and located below the level of renal veins and above the bifurcation of iliac artery
  • patients potential to receive surgery and achieve no evidence of disease (NED)
  • able to tolerate surgery
  • providing written informed consent

You may not qualify if:

  • local invasion or distant metastasis other than para-aoritc lymph nodes
  • history of other malignant tumor
  • coupled with severe systematic diseases (recent myocardial infarction, cardiomyopathy, or acute pulmonary infection)
  • emergency surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Qilu Hospital of Shandong University

Jinan, Shandong, 250012, China

Location

MeSH Terms

Conditions

Colonic Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Central Study Contacts

Yong Dai, M.D. Ph.D.

CONTACT

Xiang Zhang, M.D. Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 28, 2021

First Posted

November 22, 2021

Study Start

January 1, 2022

Primary Completion

January 1, 2024

Study Completion (Estimated)

January 1, 2027

Last Updated

November 22, 2021

Record last verified: 2021-10

Locations